Thus, using MCL1 as exemplary target, we provide evidence that our approach enables distinguishing between subgroups of tumors in order to select patients, which might profit from therapies targeting a certain GOI, and to evaluate treatment combinations <a href=https://enhanceyourlife.mom/>priligy medicine</a>